• Explore /
  • Poster
  • / Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.

Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D.

Abstract Poster

Authors

Charu Aggarwal

Charu Aggarwal

Abramson Cancer Center, Philadelphia, PA

Charu Aggarwal , Mary Weber Redman , Primo Lara Jr., Hossein Borghaei , Philip C. Hoffman , Jeffrey D. Bradley , Katie Griffin , Jieling Miao , Philip C. Mack , Vassiliki Papadimitrakopoulou , Roy S. Herbst , Karen Kelly , David R. Gandara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02965378

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9055)

DOI

10.1200/JCO.2017.35.15_suppl.9055

Abstract #

9055

Poster Bd #

381

Abstract Disclosures

Similar Posters

First Author: James Lloyd Wade III

First Author: Giorgio V. Scagliotti

First Author: Sukhmani Kaur Padda

First Author: Edwin R. Parra